Tesaro Inc. (TSRO) Shares Down 2.9%
Tesaro Inc. (NASDAQ:TSRO) was down 2.9% during trading on Wednesday . The company traded as low as $100.70 and last traded at $101.80, with a volume of 656,173 shares. The stock had previously closed at $104.79.
A number of equities research analysts have recently commented on TSRO shares. Mizuho reiterated an “outperform” rating and set a $67.00 target price on shares of Tesaro in a research note on Thursday, June 30th. Lake Street Capital reiterated a “buy” rating and set a $114.00 target price on shares of Tesaro in a research note on Tuesday, September 6th. FBR & Co reiterated a “buy” rating on shares of Tesaro in a research note on Thursday, June 30th. Wells Fargo & Co. reiterated an “outperform” rating on shares of Tesaro in a research note on Thursday, June 30th. Finally, Zacks Investment Research upgraded Tesaro from a “sell” rating to a “hold” rating in a research note on Tuesday, July 5th. Three equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. Tesaro has an average rating of “Buy” and an average target price of $94.40.
The firm’s market capitalization is $5.52 billion. The company has a 50-day moving average of $92.90 and a 200 day moving average of $63.67.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/tesaro-inc-tsro-shares-down-2-9.html
Tesaro (NASDAQ:TSRO) last released its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($1.28) EPS for the quarter, beating the consensus estimate of ($1.71) by $0.43. Tesaro had a negative return on equity of 205.63% and a negative net margin of 783.97%. The company had revenue of $36.60 million for the quarter, compared to analysts’ expectations of $4.98 million. During the same period last year, the firm posted ($1.51) earnings per share. On average, equities research analysts forecast that Tesaro Inc. will post ($7.33) EPS for the current fiscal year.
In other Tesaro news, VP Jeffrey H. Hanke sold 29,166 shares of the stock in a transaction dated Tuesday, August 30th. The stock was sold at an average price of $86.04, for a total value of $2,509,442.64. Following the transaction, the vice president now owns 29,166 shares of the company’s stock, valued at $2,509,442.64. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, VP Edward C. English sold 7,000 shares of the stock in a transaction dated Thursday, September 8th. The shares were sold at an average price of $88.54, for a total value of $619,780.00. Following the completion of the transaction, the vice president now directly owns 3,500 shares in the company, valued at approximately $309,890. The disclosure for this sale can be found here. 40.50% of the stock is owned by company insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. KCG Holdings Inc. purchased a new position in Tesaro during the second quarter worth $228,000. Quantitative Systematic Strategies LLC purchased a new position in Tesaro during the second quarter worth $240,000. Parametrica Management Ltd purchased a new position in Tesaro during the first quarter worth $251,000. Bluestein R H & Co. purchased a new position in Tesaro during the second quarter worth $252,000. Finally, Neuberger Berman Group LLC purchased a new position in Tesaro during the second quarter worth $256,000. 88.81% of the stock is currently owned by institutional investors.
Tesaro Company Profile
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. It operates in business of developing and commercializing oncology-focused therapeutics segment. It has in-licensed and are developing oncology-related product candidates, including intravenous (IV) rolapitant and niraparib, as well as product candidates under its immuno-oncology platform.
Receive News & Ratings for Tesaro Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tesaro Inc. and related companies with MarketBeat.com's FREE daily email newsletter.